Skip to main content
252 results:
1. Liberation from renal replacement therapy and early initiation to be supported by the kidney function biomarker Proenkephalin A 119-159 (penKid)  
SphingoTec announces first data on the kidney function biomarker penKid as a promising tool in supporting early initiation and liberation from RRT. Although RRT remains a pivotal measure in treating…  
2. Privacy Notice  
Privacy Policy 1. An overview of data protection General information The following information will provide you with an easy to navigate overview of what will happen with your personal data when…  
3. Media Relations  
Media Relations page  
4. Acute Kidney Injury  
Investors Relations page  
5. Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)  
Boditech Med Inc. and SphingoTec GmbH have entered into a non-exclusive royalty-bearing license agreement. Under the terms of this agreement, Boditech has obtained the rights to develop and…  
6. Biomarker Portfolio  
Nexus IB10 Biomarker Portfolio Innovative biomarker tests Standard of care biomarker tests Disclaimer Sphingotest® penKid®, sphingotest® bio-ADM®, sphingotest® DPP3 are offered for in vitro…  
Follow our Journey on Social Media View all Events View all News Events & Expos Latest News Subscribe to our Newsletter Follow the link below to subscribe to our…  
9. Clinical Evaluation  
With the mission of improving patient management in critical care settings, SphingoTec has started a series of collaboration with internationally leading academic and non-academic medical centers.  
10. COVID-19  
In severely ill COVID-19 patients, besides the main complications that include respiratory, cardiovascular and kidney diseases, an emerging body of evidence shows that endothelial function plays a…  
Search results 1 until 10 of 252